US FDA clears Quidel's Strep A test:
This article was originally published in Clinica
Quidel (US) has gained US FDA clearance for its rapid point- of-care Strep A test. The test will be marketed under two brand names - Card QS and Concise Performance Plus. "The launch of these products completes the integration of our acquisition of Pacific Biotech from Eli Lilly," said Steven Frankel, Quidel's president and CEO. Over 20 million Strep tests are performed annually in the US, generating a market of $50-60 million.